From an IC perspective, in a patient who is post-PCI/post-stent insertion for ACS, when is the aggregated risk of the patient sufficiently alarming for you to consider intensive lowering of LDL-C to a level <50 mg/dL with a PCSK9 inhibitor?

From an IC perspective, in a patient who is post-PCI/post-stent insertion for ACS, when is the aggregated risk of the patient sufficiently alarming for you to consider intensive lowering of LDL-C to a level <50 mg/dL with a PCSK9 inhibitor?

From an IC perspective, in a patient who is post-PCI/post-stent insertion for ACS, when is the aggregated risk of the patient sufficiently alarming for you to consider intensive lowering of LDL-C to a level

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Andreas Zeiher, MD

Andreas Zeiher, MD

Chairman of Medicine Department of Cardiology, Angiology, and Nephrology J. W. Goethe University Frankfurt, Germany